Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Operating Expenses (2022 - 2025)

Historic Operating Expenses for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $14.3 million.

  • BioXcel Therapeutics' Operating Expenses fell 761.59% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.4 million, marking a year-over-year decrease of 3482.63%. This contributed to the annual value of $69.5 million for FY2024, which is 5985.78% down from last year.
  • According to the latest figures from Q3 2025, BioXcel Therapeutics' Operating Expenses is $14.3 million, which was down 761.59% from $16.0 million recorded in Q2 2025.
  • BioXcel Therapeutics' 5-year Operating Expenses high stood at $53.1 million for Q4 2022, and its period low was $10.3 million during Q1 2025.
  • Its 4-year average for Operating Expenses is $29.6 million, with a median of $24.7 million in 2024.
  • In the last 5 years, BioXcel Therapeutics' Operating Expenses surged by 6329.1% in 2023 and then tumbled by 6811.75% in 2024.
  • Over the past 4 years, BioXcel Therapeutics' Operating Expenses (Quarter) stood at $53.1 million in 2022, then plummeted by 61.89% to $20.3 million in 2023, then crashed by 46.38% to $10.9 million in 2024, then surged by 31.93% to $14.3 million in 2025.
  • Its Operating Expenses was $14.3 million in Q3 2025, compared to $16.0 million in Q2 2025 and $10.3 million in Q1 2025.